Also as the evaluation of the effect of receiving ADT is usually based on the PSA level (0.2-4 ng/ml) after 7 months of ADT as an important reference point, then the indirect augmentation effect of MetS should be taken into account when deciding on the subsequent treatment regimen. Here, KLK3 is linked to metabolic syndrome.